Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis
Ronal Yosua Limen, Rudyanto Sedono, Adhrie Sugiarto, Timotius Ivan Hariyanto
Abstract
BACKGROUND: , 2021. All published studies on JAK-inhibitors and Covid-19 were collected. RESULTS: = 33%, random-effect modeling). CONCLUSIONS: This study propose that JAK-inhibitors perhaps provide advantageous effects on Covid-19 outcomes. JAK-inhibitors may be given during 1-2 weeks of disease to optimize its beneficial effects in halting the exaggerated immune response.
Topics & Concepts
Janus kinaseCoronavirus disease 2019 (COVID-19)MedicineMeta-analysisPandemic2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseVirologyInternal medicineInfectious disease (medical specialty)ReceptorOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCytokine Signaling Pathways and Interactions